Physician profile
John C Halbrook
NPI 1992782924
$23,527.62
in general payments reported to CMS, 2019-2025
82 companies · $3,913 in 2025
The $3,913 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,847 · 2020: $2,301 · 2021: $3,201 · 2022: $3,749 · 2023: $3,571 · 2024: $3,946 · 2025: $3,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,856.42 |
| Education | $573.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,496.70 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $1,304.35 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $1,253.87 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,200.11 | 2019-2025 | |
| Pfizer INC. | $1,185.95 | 2019-2025 | |
| Incyte Corporation | $1,034.74 | 2019-2025 | Monjuvi, Jakafi, Niktimvo |
| E.R. Squibb & Sons, L.L.C. | $961.36 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $888.49 | 2019-2025 | Polivy, Venclexta, Columvi |
| Amgen INC. | $804.35 | 2019-2023 | Lumakras, Kyprolis |
| Genzyme Corporation | $762.36 | 2019-2025 | |
| Abbvie INC. | $719.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $700.06 | 2020-2025 | Fruzaqla, Ninlaro, Iclusig |
| Celgene Corporation | $695.76 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Gilead Sciences, INC. | $643.88 | 2019-2025 | Trodelvy |
| Exelixis INC. | $487.82 | 2019-2025 | Cabometyx |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $451.41 | 2019-2022 | |
| Astellas Pharma US INC | $445.29 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Eisai INC. | $435.04 | 2019-2025 | |
| Lilly USA, LLC | $434.34 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $421.59 | 2019-2025 | Libtayo |
| Daiichi Sankyo INC. | $386.61 | 2019-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $372.24 | 2020-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $339.22 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $335.43 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Emd Serono, INC. | $323.34 | 2019-2025 | Bavencio |
| Glaxosmithkline, LLC. | $303.02 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Karyopharm Therapeutics INC. | $296.69 | 2020-2025 | Xpovio |
| Tosoh Bioscience, INC. | $279.00 | 2019 | |
| Seagen INC. | $255.82 | 2020-2023 | Adcetris |
| Puma Biotechnology, INC. | $250.01 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $225.06 | 2019-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $213.41 | 2019-2025 | |
| Array Biopharma INC | $211.60 | 2020-2025 | Braftovi, Mektovi, Tukysa |
| Myriad Genetic Laboratories, INC. | $204.91 | 2021-2023 | Bracanalysis Cdx |
| Aveo Pharmaceuticals, INC. | $201.40 | 2022-2025 | Fotivda |
| Kite Pharma, INC. | $183.67 | 2020-2023 | Yescarta |
| Beone Medicines USA, INC. | $166.40 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $162.22 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $149.09 | 2019-2022 | |
| Pharmaessentia USA Corporation | $144.21 | 2022-2025 | Besremi |
| Genmab U.S., INC. | $139.78 | 2023-2025 | Tivdak, Epkinly |
| Blueprint Medicines Corporation | $137.64 | 2020-2022 | |
| Morphosys, US INC. | $133.73 | 2021-2023 | Monjuvi |
| Stemline Therapeutics INC. | $120.10 | 2023-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $119.94 | 2020-2024 | Cosela |
| Acceleron Pharma, INC. | $107.51 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.01 | 2019-2025 | |
| G1 Therapeutics, INC. | $96.25 | 2022-2023 | Cosela |
| Coherus Oncology, INC. | $94.33 | 2020-2024 | |
| Springworks Therapeutics, INC. | $76.49 | 2024-2025 | Ogsiveo |
| Octapharma USA, INC. | $70.60 | 2020 | |
| Spectrum Pharmaceuticals INC. | $65.86 | 2024-2025 | Rolvedon |
| Sobi, INC | $60.46 | 2022-2023 | |
| Tersera Therapeutics LLC | $59.15 | 2021-2023 | Zoladex |
| Adc Therapeutics America, INC. | $56.48 | 2021-2023 | |
| Mirati Therapeutics, INC. | $56.02 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $54.13 | 2019-2025 | Pyrukynd |
| Intuitive Surgical, INC. | $50.16 | 2025 | |
| Kyowa Kirin, INC. | $47.95 | 2021-2022 | |
| Foundation Medicine, INC. | $47.82 | 2022-2023 | |
| Legend Biotech USA INC. | $45.47 | 2025 | Carvykti |
| Dova Pharmaceuticals | $36.29 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $35.22 | 2019-2020 | |
| Tesaro, INC. | $33.71 | 2019 | |
| Caris Mpi, INC. | $32.36 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $28.22 | 2023 | Odomzo, Yonsa |
| Secura Bio, INC. | $27.76 | 2020-2022 | |
| Clovis Oncology, INC. | $24.77 | 2019-2020 | |
| Immunogen, INC. | $24.22 | 2023 | Elahere |
| Sanofi US Services INC. | $22.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.26 | 2019-2020 | |
| Tg Therapeutics, INC. | $20.92 | 2021 | |
| Dendreon Pharmaceuticals LLC | $19.43 | 2025 | Provenge |
| Immunomedics, INC. | $18.12 | 2020 | |
| Novocure INC. | $17.65 | 2024 | Optune Lua (Novottf-200t) |
| Geron Corporation | $17.05 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $16.48 | 2022 | |
| Fresenius Kabi USA, LLC | $16.02 | 2025 | Stimufend |
| Aurobindo Pharma USA, INC. | $13.22 | 2020 | |
| Verastem, INC. | $11.99 | 2019 | |
| Deciphera Pharmaceuticals INC. | $11.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
Keytruda $666Opdivo $439Venclexta $423Lynparza $372Erleada $363Darzalex $362Libtayo $354Monjuvi $330Trodelvy $324Xtandi $322Enhertu $320Polivy $303Reblozyl $291Imfinzi $289Sarclisa $272Lenvima $235Pluvicto $234Tecvayli $226Brukinsa $215Akeega $210Jaypirca $205Talzenna $194Fruzaqla $192Tukysa $191Cabometyx $190Bracanalysis Cdx $182Rezlidhia $170Tavalisse $170Orgovyx $161Kisqali $160Verzenio $157Fotivda $155Jakafi $150Talvey $150Columvi $150Xpovio $146Imbruvica $143Adcetris $143Ibrance $141Zejula $138Jemperli $138Braftovi $136Scemblix $132Besremi $126Cosela $124Orserdu $120Lutathera $118Mektovi $117Rybrevant $111Welireg $108Epkinly $102Paxlovid $96.34Nubeqa $90.95Vitrakvi $90.32Inlyta $90.06Tivdak $88.76Elrexfio $88.67Ninlaro $87.56Balversa $85.31Iclusig $83.79Zepzelca $74.15Stivarga $73.67Xofigo $69.33Inqovi $68.01Lonsurf $68.01Rolvedon $65.86Elahere $65.45Lorbrena $62.00Comirnaty $60.80Vyloy $60.72Tevimbra $59.55Ogsiveo $58.29Krazati $56.02Lumakras $55.55Bavencio $54.64Da Vinci Surgical System $50.16Padcev $50.07Opdualag $47.26Bosulif $46.76Jevtana $45.59Carvykti $45.47Xalkori $45.03Tecentriq $39.99Ojjaara $38.53Tasigna $38.41Tagrisso $36.39Pomalyst $34.55Yescarta $34.47Mi Cancer Seek $32.36Itovebi $29.40Nerlynx $28.80Loqtorzi $28.33Yonsa $28.22Odomzo $28.22Datroway $27.88Xospata $27.00Ziihera $26.83Mekinist $24.41Zoladex $23.84Udenyca $22.68
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Halbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.